Aquestive Therapeutics vs Tonix Pharmaceuticals
AQST and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and TNXP compare
Aquestive Therapeutics is the larger company, worth 9.2 times as much as Tonix Pharmaceuticals ($464M against $50.4M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus 22.6% for Aquestive Therapeutics).
Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −549% at Tonix Pharmaceuticals.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $50.4M |
| Share price | $3.70 | $2.94 |
| Change, 1 year | −31.4% | −81.5% |
| Change, 5 years | −41.9% | −100.0% |
| Beta (5Y) | 1.20 | 0.75 |
| Employees | 147 | 142 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.6× | 1.7× (better) |
| P/B | – | 0.2× |
| FCF yield | −9.9% (better) | −314% |
| Fair value | – | $16.91 |
| Margin of safety | – | 82.6% |
| Growth | ||
| Revenue growth (TTM) | 22.6% | 196% (better) |
| Revenue growth, 5Y average | −0.58% | – |
| Profitability | ||
| Gross margin | 67.0% | 83.8% (better) |
| Operating margin | −97.5% (better) | −568% |
| Net margin | −145% (better) | −549% |
| FCF margin | −85.0% (better) | −543% |
| Return on equity | – | −81.8% |
| Return on invested capital | – | −298% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.7× | – |
| Current ratio | 7.19 (better) | 6.61 |
| Altman Z-score | −3.57 (better) | −5.42 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −427% |
| Shareholder yield | 0.00% (better) | −427% |
| Ownership | ||
| Held by institutions | 57.4% | 54.6% |
| Held by insiders | 3.2% | 0.27% |
| Insider net buying, 12 months | −$2.3M | $479K (better) |
| Short interest, % of float | 24.1% | 19.4% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.